Literature DB >> 22531170

Application of a BRAF V600E mutation-specific antibody for the diagnosis of hairy cell leukemia.

Mindaugas Andrulis1, Roland Penzel, Wilko Weichert, Andreas von Deimling, David Capper.   

Abstract

In recent times BRAF V600E mutations have emerged as a genetic hallmark of hairy cell leukemia (HCL). This specific point mutation is present in virtually all cases of HCL but is exceedingly rare in other peripheral B-cell neoplasms. In this study we investigated the application of a BRAF V600E mutation-specific antibody (clone VE1) to differentiate HCL from HCL mimics, such as HCL variant and splenic marginal zone lymphoma. A total of 52 routinely processed formalin-fixed paraffin-embedded tissue specimens were investigated (bone marrow, n=46; spleen, n=6) for expression of V600E-mutated BRAF protein. All 32 cases of HCL were scored positive, and all non-HCL cases were scored negative. In 28 of 30 HCL cases the presence of a BRAF V600E mutation could be confirmed by direct sequencing, whereas no BRAF mutations were detected among 20 HCL mimics. We further screened 228 mature B-cell neoplasms with VE1 and detected 1 positive case of chronic lymphocytic leukemia. Sequencing confirmed the presence of a BRAF V600E mutation. In conclusion, we demonstrate that VE1 immunohistochemistry can be used to reliably differentiate HCL from HCL-mimicking entities. This on-slide technique might be particularly helpful in interpreting challenging biopsies with low tumor content.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22531170     DOI: 10.1097/PAS.0b013e3182549b50

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  34 in total

1.  [Bone marrow diagnostics: integrative evaluation of results is a duty].

Authors:  F Fend
Journal:  Pathologe       Date:  2012-11       Impact factor: 1.011

2.  Immunohistochemical analysis using a BRAF V600E mutation specific antibody is highly sensitive and specific for the diagnosis of hairy cell leukemia.

Authors:  Xuan J Wang; Annette Kim; Shaoying Li
Journal:  Int J Clin Exp Pathol       Date:  2014-06-15

3.  Frequent BRAFV600E mutation has no effect on tumor invasiveness in patients with Langerhans cell histiocytosis.

Authors:  Rui Wei; Zhongqing Wang; Xiaolin Li; Yigang Shu; Bin Fu
Journal:  Biomed Rep       Date:  2013-01-25

Review 4.  [Predictive molecular pathological stratification of hematological neoplasms].

Authors:  M Andrulis
Journal:  Pathologe       Date:  2016-11       Impact factor: 1.011

Review 5.  [Hairy cell leukemia].

Authors:  S Dietrich; M Andrulis; T Zenz
Journal:  Internist (Berl)       Date:  2015-04       Impact factor: 0.743

6.  The use of BRAF V600E mutation-specific immunohistochemistry in pediatric Langerhans cell histiocytosis.

Authors:  Leomar Y Ballester; Miguel D Cantu; Karen P H Lim; Stephen F Sarabia; Lizmery Suarez Ferguson; C Renee Webb; Carl E Allen; Kenneth L McClain; Carrie A Mohila; Jyotinder N Punia; Angshumoy Roy; Dolores H López-Terrada; M John Hicks; Kevin E Fisher
Journal:  Hematol Oncol       Date:  2017-02-20       Impact factor: 5.271

7.  BRAF V600E immunohistochemistry is reliable in primary and metastatic colorectal carcinoma regardless of treatment status and shows high intratumoral homogeneity.

Authors:  Jacob R Bledsoe; Michal Kamionek; Mari Mino-Kenudson
Journal:  Am J Surg Pathol       Date:  2014-10       Impact factor: 6.394

8.  A comprehensive immunophenotypic marker analysis of hairy cell leukemia in paraffin-embedded bone marrow trephine biopsies--a tissue microarray study.

Authors:  Judit Tóth-Lipták; Klára Piukovics; Zita Borbényi; Judit Demeter; Enikő Bagdi; László Krenács
Journal:  Pathol Oncol Res       Date:  2014-06-06       Impact factor: 3.201

9.  Treatment of refractory hairy cell leukemia with a BRAF-inhibitor: lessons to be learnt.

Authors:  Eszter Sári; Zsolt György Nagy; Kornélia Baghy; Hajnalka Rajnai; Csaba Bödör; Judit Csomor; Gábor Barna; Gábor Rudas; Ilona Kovalszky; Judit Demeter
Journal:  Pathol Oncol Res       Date:  2014-05-03       Impact factor: 3.201

10.  Monoclonal antibody HBME-1 reacts with a minor subset of B cells with villous surface and can be useful in the diagnosis of hairy cell leukemia and other indolent lymphoproliferations of villous B lymphocytes.

Authors:  László Krenács; Judit Tóth-Lipták; Judit Demeter; Klára Piukovics; Zita Borbényi; Péter Gogolák; Eszter Sári; Enikő Bagdi
Journal:  Virchows Arch       Date:  2013-10-05       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.